This article is among a series of articles published in the Lancet journal on the topic of clinical trials in global health. This piece specifically discusses how the research community responded to the Covid-19 pandemic and lays out the attendant challenges.
Key among the challenges discussed is a negative new norm of publishing that focuses on quantity over quality, as well as clinical trials with very limited scale as to provide meaningful conclusive evidence.
The paper also highlights the capacity and infrastructure gaps in LMICs and how that leads to a lack of valid research outputs.
The paper has good insights on how this negative trend in global health can be addressed, and hopes Covid-19 is a turning point that brings about better coordination and collaboration within the medical research community, if only there is buy-in.
Read full article here.